RARA and acute myeloid leukemia: Given the higher expression of miR-128a in AML with mature phenotypes and with FLT3 or PML/RARα alterations, we decided to inhibit miR-128a maturation in leukemic cells of these subsets of patients to stimulate further propensity to cell differentiation.